OneMedNet Corp

ONMD Nasdaq Services-Commercial Physical & Biological Research Financials FY2022–FY2025

OneMedNet Corp had $1.4M of revenue in fiscal 2025, up 111.4% on the year before.

Last close · Oct 23, 2026

$4.71

4.1%

Earnings calendar · OneMedNet Corp

Every quarter, companies publish how much they sold and earned. These are the days OneMedNet Corp did it, and the next one. Share prices often move a lot on those days.

Next results

November 13, 2026

Friday · in 17 days

Time: Time not announced
Covers: Period ended Sep 30, 2026
Source: Earnings calendar

See who else reports that week →

Date	Results for	Time	Source
Aug 14, 2026	Q2 '26	After the market closes	10-Q ↗
May 15, 2026	Q1 '26	After the market closes	10-Q ↗
Mar 30, 2026	Q4 '25	After the market closes	10-K ↗
Nov 14, 2025	Q3 '25	After the market closes	10-Q ↗
Aug 13, 2025	Q2 '25	After the market closes	10-Q ↗
May 14, 2025	Q1 '25	After the market closes	10-Q ↗
Apr 15, 2025	Q4 '24	After the market closes	10-K ↗
Dec 17, 2024	Q3 '24	After the market closes	10-Q ↗

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read OneMedNet Corp’s latest annual report (fiscal 2025). Here is what stands out:

1 strength 3 to watch

1.Sales and profit

See section →

OneMedNet Corp had $1.4M of revenue in fiscal 2025, up 111.4% on the year before.
Its operating margin was −711.3%, up 782.4 pts: of every 100 in sales, about −711 is left after running the business.
OneMedNet Corp lost $2.8M in fiscal 2025.

2.Cash and shareholders

See section →

Free cash flow was −$7.5M in fiscal 2025, −553.1% of revenue.
In the last 12 months, insiders bought $4.2M and sold $0.2M of shares on the open market.

3.Financial health

See section →

OneMedNet Corp owes $0.6M more than it holds in cash.
OneMedNet Corp passes 5 of 9 financial health tests (Piotroski F-score).

OneMedNet Corp in 30 seconds

Good So-so Weak

Are sales growing?

+111.4%

Yes. Sales grew 111.4% last year.

Does it make a profit?

−206.1%

No. It lost money last year.

Does profit turn into cash?

−553.1%

No. It spent more cash than it brought in.

How healthy are the accounts?

5 / 9

Mixed. It passes 5 of 9 health tests.

How is the share priced?

—

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap

$273M

Oct 23 close

P/E

—

On −$0.15 EPS (TTM)

Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA · OneMedNet Corp had $1.4M of revenue in fiscal 2025, up 111.4% on the year before. Its operating margin was −711.3%, up 782.4 pts: of every 100 in sales, about −711 is left after running the business.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

FY22

Revenue $1.2M

FY23

Revenue $1.0M

FY24

Revenue $0.6M

FY25

Revenue $1.4M

Revenue

Q3 '23

Revenue $0.3M

Q4 '23

Revenue $0.3M

Q1 '24

Revenue $0.2M

Q2 '24

Revenue $0.2M

Q3 '24

Revenue $0.1M

Q4 '24

Revenue $0.0M

Q1 '25

Revenue $0.1M

Q2 '25

Revenue $0.2M

Q3 '25

Revenue $0.2M

Q4 '25

Revenue $0.9M

Q1 '26

Revenue $0.1M

Q2 '26

Revenue $0.3M

Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Margins, % of revenue

FY22

Gross −31.2%

Operating −669.1%

Net −2,641.0%

FCF −412.9%

FY23

Gross −12.6%

Operating −671.2%

Net −3,308.5%

FCF −473.6%

FY24

Gross −43.7%

Operating −1,493.8%

Net −1,575.3%

FCF −1,089.1%

FY25

Gross −37.0%

Operating −711.3%

Net −206.1%

FCF −553.1%

Gross Operating Net FCF

Margins, % of revenue

Q3 '23

Gross 10.1%

Operating −591.1%

Net −4,245.4%

FCF −343.9%

Q4 '23

Gross 0.6%

Operating −549.4%

Net −734.1%

FCF −512.1%

Q1 '24

Gross −27.8%

Operating −847.2%

Net −850.4%

FCF −626.2%

Q2 '24

Gross −44.9%

Operating −1,081.1%

Net −1,581.1%

FCF −663.9%

Q3 '24

Gross −59.2%

Operating −1,645.1%

Net −1,449.3%

FCF −1,346.5%

Q4 '24

Gross −100.0%

Operating −10,446.2%

Net −9,126.9%

FCF −7,811.5%

Q1 '25

Gross −163.5%

Operating −1,623.4%

Net −1,388.3%

FCF −1,356.9%

Q2 '25

Gross −155.5%

Operating −1,331.0%

Net 1,923.9%

FCF −1,414.2%

Q3 '25

Gross −125.4%

Operating −1,262.7%

Net −418.6%

FCF −987.0%

Q4 '25

Gross 18.5%

Operating −345.9%

Net −352.4%

FCF −192.8%

Q1 '26

Gross −395.8%

Operating −2,658.3%

Net −2,555.2%

FCF −1,608.3%

Q2 '26

Gross −193.5%

Operating −774.3%

Net −743.8%

FCF −645.2%

Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Operating Net FCF

Net income and earnings per share

KIRA · OneMedNet Corp lost $2.8M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

FY22

Net income −$30.5M

FY23

Net income −$33.8M

FY24

Net income −$10.1M

FY25

Net income −$2.8M

Net income

Q3 '23

Net income −$13.8M

Q4 '23

Net income −$2.5M

Q1 '24

Net income −$2.1M

Q2 '24

Net income −$3.6M

Q3 '24

Net income −$2.1M

Q4 '24

Net income −$2.4M

Q1 '25

Net income −$1.9M

Q2 '25

Net income $3.0M

Q3 '25

Net income −$0.7M

Q4 '25

Net income −$3.1M

Q1 '26

Net income −$2.5M

Q2 '26

Net income −$2.2M

Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Diluted EPS

FY22

Diluted EPS −$7.66

FY23

Diluted EPS −$4.65

FY24

Diluted EPS −$0.36

FY25

Diluted EPS −$0.06

Diluted EPS

Q3 '23

Diluted EPS −$3.23

Q4 '23

Diluted EPS $2.90

Q1 '24

Diluted EPS −$0.08

Q2 '24

Diluted EPS −$0.14

Q3 '24

Diluted EPS −$0.07

Q4 '24

Diluted EPS −$0.07

Q1 '25

Diluted EPS −$0.06

Q2 '25

Diluted EPS $0.07

Q3 '25

Diluted EPS −$0.01

Q4 '25

Diluted EPS −$0.06

Q1 '26

Diluted EPS −$0.04

Q2 '26

Diluted EPS −$0.04

Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA · Free cash flow was −$7.5M in fiscal 2025, −553.1% of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

FY22

Free cash flow −$4.8M

FY23

Free cash flow −$4.8M

FY24

Free cash flow −$7.0M

FY25

Free cash flow −$7.5M

Free cash flow

Q3 '23

Free cash flow −$1.1M

Q4 '23

Free cash flow −$1.7M

Q1 '24

Free cash flow −$1.6M

Q2 '24

Free cash flow −$1.5M

Q3 '24

Free cash flow −$1.9M

Q4 '24

Free cash flow −$2.0M

Q1 '25

Free cash flow −$1.9M

Q2 '25

Free cash flow −$2.2M

Q3 '25

Free cash flow −$1.7M

Q4 '25

Free cash flow −$1.7M

Q1 '26

Free cash flow −$1.5M

Q2 '26

Free cash flow −$1.9M

Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cash from operations vs capital spending

FY22

Cash from operations −$4.7M

Capital spending $0.1M

FY23

Cash from operations −$4.8M

Capital spending $0.0M

FY24

Cash from operations −$7.0M

Capital spending $0.1M

FY25

Cash from operations −$7.5M

Capital spending $0.0M

Cash from operations Capital spending

Cash from operations vs capital spending

Q3 '23

Cash from operations −$1.1M

Capital spending $0.0M

Q4 '23

Cash from operations −$1.7M

Capital spending $0.0M

Q1 '24

Cash from operations −$1.5M

Capital spending $0.0M

Q2 '24

Cash from operations −$1.5M

Capital spending $0.0M

Q3 '24

Cash from operations −$1.9M

Capital spending $0.0M

Q4 '24

Cash from operations −$2.0M

Capital spending $0.0M

Q1 '25

Cash from operations −$1.9M

Capital spending $0.0M

Q2 '25

Cash from operations −$2.2M

Capital spending $0.0M

Q3 '25

Cash from operations −$1.7M

Capital spending $0.0M

Q4 '25

Cash from operations −$1.7M

Capital spending $0.0M

Q1 '26

Cash from operations −$1.5M

Capital spending $0.0M

Q2 '26

Cash from operations −$1.9M

Capital spending $0.0M

Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

FY22

Dividends —

Buybacks —

FY23

Dividends —

Buybacks —

FY24

Dividends —

Buybacks —

FY25

Dividends —

Buybacks —

Dividends Buybacks

Diluted shares outstanding (annual)

FY22

Diluted shares 0.00B

FY23

Diluted shares 0.01B

FY24

Diluted shares 0.03B

FY25

Diluted shares 0.04B

Insider trades

KIRA · In the last 12 months, insiders bought $4.2M and sold $0.2M of shares on the open market.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$4.2M

3 insiders

Sold, 12 months

$0.2M

2 insiders

Of sales under plans

$0.0M

Date	Insider	Trade	Shares	Price	Value	Filing
Oct 9, 2026	Jeffrey YuChief Medical Officer, Director, 10% owner	Bought	45,126	$5.54	$0.2M	Form 4
Oct 7, 2026	Thomas KosasaDirector, 10% owner	Bought	129,758	$5.78	$0.8M	Form 4
Sep 24, 2026	Aaron GreenChief Executive Officer, Director	Sold	1,667	$6.48	$0.0M	Form 4
Sep 22, 2026	Aaron GreenChief Executive Officer, Director	Sold	5,000	$7.39	$0.0M	Form 4
Sep 21, 2026	Robert Lawrence GoldenChief Financial Officer, Director	Sold	3,000	$6.63	$0.0M	Form 4
Sep 15, 2026	Robert Lawrence GoldenChief Financial Officer, Director	Sold	3,000	$6.30	$0.0M	Form 4
Sep 14, 2026	Robert Lawrence GoldenChief Financial Officer, Director	Sold	2,500	$6.60	$0.0M	Form 4
Sep 10, 2026	Jeffrey YuChief Medical Officer, Director, 10% owner	Bought	142,857	$0.63	$0.1M	Form 4
Jul 30, 2026	Thomas KosasaDirector, 10% owner	Bought	1,449,275	$0.69	$1.0M	Form 4
Jun 23, 2026	Jeffrey YuChief Medical Officer, Director, 10% owner	Bought	158,730	$0.63	$0.1M	Form 4
Jun 23, 2026	Aaron GreenChief Executive Officer, Director	Bought	36,650	$0.57	$0.0M	Form 4
Jun 16, 2026	Jeffrey YuChief Medical Officer, Director, 10% owner	Bought	172,414	$0.58	$0.1M	Form 4
Jun 15, 2026	Aaron GreenChief Executive Officer, Director	Bought	18,702	$0.54	$0.0M	Form 4
Jun 12, 2026	Thomas KosasaDirector, 10% owner	Bought	158,730	$0.63	$0.1M	Form 4
Jun 12, 2026	Aaron GreenChief Executive Officer, Director	Bought	36,920	$0.56	$0.0M	Form 4
May 18, 2026	Thomas KosasaDirector, 10% owner	Bought	268,817	$0.93	$0.2M	Form 4
Apr 23, 2026	Thomas KosasaDirector, 10% owner	Bought	280,898	$0.89	$0.2M	Form 4
Apr 1, 2026	Jeffrey YuChief Medical Officer, Director, 10% owner	Bought	903,614	$0.83	$0.7M	Form 4
Feb 6, 2026	Thomas KosasaDirector, 10% owner	Bought	595,238	$0.84	$0.5M	Form 4
Nov 18, 2025	Aaron GreenChief Executive Officer, Director	Sold	61,555	$1.20	$0.1M	Form 4
Oct 22, 2025	Aaron GreenChief Executive Officer, Director	Sold	64,767	$2.23	$0.1M	Form 4
Oct 15, 2025	Eric CasaburiDirector	Bought	10,000	$3.05	$0.0M	Form 4
Sep 25, 2025	Jeffrey YuChief Medical Officer, Director	Bought	1,250	$1.03	$0.0M	Form 4
Sep 24, 2025	Thomas KosasaDirector	Bought	6,000	$0.93	$0.0M	Form 4
Sep 24, 2025	Jeffrey YuChief Medical Officer, Director	Bought	17,200	$1.02	$0.0M	Form 4
Sep 23, 2025	Jeffrey YuChief Medical Officer, Director	Bought	5,700	$0.93	$0.0M	Form 4
Sep 22, 2025	Jeffrey YuChief Medical Officer, Director	Bought	400	$0.95	$0.0M	Form 4
Sep 19, 2025	Jeffrey YuChief Medical Officer, Director	Bought	1,250	$0.89	$0.0M	Form 4
Sep 18, 2025	Jeffrey YuChief Medical Officer, Director	Bought	700	$0.91	$0.0M	Form 4
Sep 5, 2025	Jeffrey YuChief Medical Officer, Director	Bought	2,100	$0.86	$0.0M	Form 4
Sep 4, 2025	Jeffrey YuChief Medical Officer, Director	Bought	11,810	$0.87	$0.0M	Form 4
Sep 3, 2025	Jeffrey YuChief Medical Officer, Director	Bought	11,670	$0.81	$0.0M	Form 4
Sep 2, 2025	Jeffrey YuChief Medical Officer, Director	Bought	24,319	$0.85	$0.0M	Form 4
Aug 29, 2025	Thomas KosasaDirector	Bought	581,395	$0.86	$0.5M	Form 4
Aug 29, 2025	Jeffrey YuChief Medical Officer, Director	Bought	10,890	$0.82	$0.0M	Form 4
Aug 28, 2025	Jeffrey YuChief Medical Officer, Director	Bought	17,000	$0.80	$0.0M	Form 4
Aug 27, 2025	Jeffrey YuChief Medical Officer, Director	Bought	21,374	$0.69	$0.0M	Form 4
Aug 26, 2025	Jeffrey YuChief Medical Officer, Director	Bought	173,350	$0.69	$0.1M	Form 4
Aug 25, 2025	Jeffrey YuChief Medical Officer, Director	Bought	13,300	$0.75	$0.0M	Form 4
Aug 21, 2025	Jeffrey YuChief Medical Officer, Director	Bought	15,000	$0.77	$0.0M	Form 4
Aug 19, 2025	Jeffrey YuChief Medical Officer, Director	Bought	16,500	$0.77	$0.0M	Form 4
Apr 21, 2025	Thomas KosasaDirector	Bought	47,000	$0.49	$0.0M	Form 4
Dec 18, 2024	Jeffrey YuChief Medical Officer, Director	Bought	100	$0.99	$0.0M	Form 4
Nov 20, 2024	Eric CasaburiDirector	Bought	1,300	$0.87	$0.0M	Form 4
Nov 12, 2024	Eric CasaburiDirector	Bought	500	$0.85	$0.0M	Form 4
Sep 20, 2024	Jeffrey YuChief Medical Officer, Director	Bought	1,600	$0.66	$0.0M	Form 4
Sep 18, 2024	Jeffrey YuChief Medical Officer, Director	Bought	800	$0.68	$0.0M	Form 4
Aug 21, 2024	Jeffrey YuChief Medical Officer, Director	Bought	100	$1.22	$0.0M	Form 4
Aug 16, 2024	Jeffrey YuChief Medical Officer, Director	Bought	14	$1.41	$0.0M	Form 4
Aug 15, 2024	Jeffrey YuChief Medical Officer, Director	Bought	10	$1.34	$0.0M	Form 4
Aug 14, 2024	Jeffrey YuChief Medical Officer, Director	Bought	13	$1.35	$0.0M	Form 4
Aug 13, 2024	Jeffrey YuChief Medical Officer, Director	Bought	2,237	$1.19	$0.0M	Form 4
Aug 12, 2024	Jeffrey YuChief Medical Officer, Director	Bought	913	$1.10	$0.0M	Form 4
Jul 8, 2024	Eric CasaburiDirector	Bought	4,100	$0.92	$0.0M	Form 4
May 10, 2024	Jeffrey YuChief Medical Officer, Director	Bought	1,203	$0.52	$0.0M	Form 4
May 8, 2024	Jeffrey YuChief Medical Officer, Director	Bought	105	$0.69	$0.0M	Form 4
May 7, 2024	Jeffrey YuChief Medical Officer, Director	Bought	106	$0.68	$0.0M	Form 4
May 6, 2024	Jeffrey YuChief Medical Officer, Director	Bought	214	$0.65	$0.0M	Form 4
May 3, 2024	Jeffrey YuChief Medical Officer, Director	Bought	350	$0.60	$0.0M	Form 4
May 2, 2024	Jeffrey YuChief Medical Officer, Director	Bought	100	$0.62	$0.0M	Form 4
Apr 24, 2024	Jeffrey YuChief Medical Officer, Director	Bought	100	$0.65	$0.0M	Form 4
Mar 22, 2024	Jeffrey YuChief Medical Officer, Director	Bought	100	$0.79	$0.0M	Form 4
Mar 6, 2024	Jeffrey YuChief Medical Officer, Director	Bought	16	$0.84	$0.0M	Form 4
Mar 5, 2024	Eric CasaburiDirector	Bought	2,000	$0.74	$0.0M	Form 4
Feb 29, 2024	Eric CasaburiDirector	Bought	575	$0.72	$0.0M	Form 4
Feb 16, 2024	Jeffrey YuChief Medical Officer, Director	Bought	100	$0.82	$0.0M	Form 4
Feb 16, 2024	Eric CasaburiDirector	Bought	2,000	$0.77	$0.0M	Form 4
Feb 8, 2024	Jeffrey YuChief Medical Officer, Director	Bought	2	$1.19	$0.0M	Form 4
Feb 1, 2024	Jeffrey YuChief Medical Officer, Director	Bought	1,357	$1.45	$0.0M	Form 4
Jan 30, 2024	Jeffrey YuChief Medical Officer, Director	Bought	400	$1.14	$0.0M	Form 4
Jan 29, 2024	Jeffrey YuChief Medical Officer, Director	Bought	950	$1.04	$0.0M	Form 4
Jan 26, 2024	Jeffrey YuChief Medical Officer, Director	Bought	5,386	$0.56	$0.0M	Form 4
Jan 25, 2024	Jeffrey YuChief Medical Officer, Director	Bought	2,304	$0.55	$0.0M	Form 4
Jan 24, 2024	Jeffrey YuChief Medical Officer, Director	Bought	740	$0.55	$0.0M	Form 4
Jan 23, 2024	Jeffrey YuChief Medical Officer, Director	Bought	720	$0.52	$0.0M	Form 4
Jan 22, 2024	Jeffrey YuChief Medical Officer, Director	Bought	5,035	$0.49	$0.0M	Form 4
Jan 19, 2024	Jeffrey YuChief Medical Officer, Director	Bought	60	$0.48	$0.0M	Form 4
Jan 17, 2024	Jeffrey YuChief Medical Officer, Director	Bought	362	$0.61	$0.0M	Form 4
Jan 16, 2024	Jeffrey YuChief Medical Officer, Director	Bought	15	$0.75	$0.0M	Form 4
Jan 12, 2024	Jeffrey YuChief Medical Officer, Director	Bought	20	$0.81	$0.0M	Form 4
Jan 10, 2024	Jeffrey YuChief Medical Officer, Director	Bought	20	$0.85	$0.0M	Form 4
Jan 9, 2024	Jeffrey YuChief Medical Officer, Director	Bought	100	$0.86	$0.0M	Form 4
Jan 8, 2024	Jeffrey YuChief Medical Officer, Director	Bought	10	$0.83	$0.0M	Form 4
Jan 4, 2024	Jeffrey YuChief Medical Officer, Director	Bought	180	$0.84	$0.0M	Form 4
Jan 2, 2024	Jeffrey YuChief Medical Officer, Director	Bought	20	$0.82	$0.0M	Form 4
Dec 27, 2023	Jeffrey YuChief Medical Officer, Director	Bought	10	$1.03	$0.0M	Form 4
Dec 15, 2023	Jeffrey YuChief Medical Officer, Director	Bought	10	$0.92	$0.0M	Form 4
Dec 13, 2023	Jeffrey YuChief Medical Officer, Director	Bought	50	$1.09	$0.0M	Form 4
Dec 12, 2023	Jeffrey YuChief Medical Officer, Director	Bought	3,040	$1.06	$0.0M	Form 4
Dec 11, 2023	Jeffrey YuChief Medical Officer, Director	Bought	30	$1.36	$0.0M	Form 4
Dec 8, 2023	Jeffrey YuChief Medical Officer, Director	Bought	3,300	$1.31	$0.0M	Form 4
Dec 7, 2023	Robert Lawrence GoldenChief Financial Officer, Director	Bought	300	$1.71	$0.0M	Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA · OneMedNet Corp owes $0.6M more than it holds in cash.

Cash, debt and the ratios that show how comfortably OneMedNet Corp can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

FY22

Cash $0.3M

Debt —

FY23

Cash $0.0M

Debt $0.9M

FY24

Cash $0.2M

Debt $4.6M

FY25

Cash $0.6M

Debt $1.2M

Cash Debt

Fiscal year end	FY22	FY23	FY24	FY25
Cash and short-term investments	$0.3M	$0.0M	$0.2M	$0.6M
Debt incl. finance leases	—	$0.9M	$4.6M	$1.2M
Interest coverage	−19.1x	−623.0x	−65.3x	−144.3x
Current ratio	0.0x	0.0x	0.2x	0.4x
Quick ratio	0.0x	0.0x	0.2x	0.4x
Total assets	$1.3M	$0.5M	$3.7M	$2.2M
Total liabilities	$27.6M	$13.9M	$19.7M	$5.1M
Shareholders' equity	−$26.4M	−$13.4M	−$16.0M	−$3.0M
Net debt (− = net cash)	—	$0.9M	$4.5M	$0.6M

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

FY22

Return on capital —

Return on equity —

Return on assets −2,362.4%

FY23

Return on capital —

Return on equity —

Return on assets −3,854.0%

FY24

Return on capital —

Return on equity —

Return on assets −483.4%

FY25

Return on capital —

Return on equity —

Return on assets −95.3%

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA · OneMedNet Corp passes 5 of 9 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

Test	FY22	FY23	FY24	FY25
Net income is positive	✕	✕	✕	✕
Cash from operations is positive	✕	✕	✕	✕
Return on assets rose	—	✕	✓	✓
Cash from operations exceeds net income	✓	✓	✓	✕
Debt fell relative to assets	—	—	✓	✓
Current ratio rose	—	✓	✓	✓
Share count didn't rise	—	✕	✕	✕
Gross margin rose	—	✓	✕	✓
Revenue rose relative to assets	—	✓	✕	✓
F-score	— / 3	4 / 8	4 / 9	5 / 9
Accruals ratio	−1,997.5%	−3,307.4%	−151.6%	160.0%
Altman Z''	−317.91	−933.19	−134.49	−197.32

All figures

Every number, year by year.

4 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV

Fiscal year	FY22	FY23	FY24	FY25
Income statement
Revenue	$1.2M	$1.0M	$0.6M	$1.4M
Gross profit	−$0.4M	−$0.1M	−$0.3M	−$0.5M
Research and development	$1.6M	$2.1M	$1.5M	$1.5M
Operating income	−$7.7M	−$6.9M	−$9.6M	−$9.7M
Interest expense	$0.4M	$0.0M	$0.1M	$0.1M
Pretax income	−$30.4M	−$33.8M	−$10.1M	−$2.8M
Income tax	$0.0M	$0.0M	$0.0M	$0.0M
Net income	−$30.5M	−$33.8M	−$10.1M	−$2.8M
Diluted EPS	−$7.66	−$4.65	−$0.36	−$0.06
Diluted shares	0.00B	0.01B	0.03B	0.04B
Cash flow
Cash from operations	−$4.7M	−$4.8M	−$7.0M	−$7.5M
Capital expenditure	$0.1M	$0.0M	$0.1M	$0.0M
Free cash flow	−$4.8M	−$4.8M	−$7.0M	−$7.5M
Depreciation and amortization	$0.0M	$0.0M	$0.1M	$0.1M
Stock-based compensation	$1.9M	$1.5M	$0.6M	$2.0M
Balance sheet
Cash and short-term investments	$0.3M	$0.0M	$0.2M	$0.6M
Total debt	—	$0.9M	$4.6M	$1.2M
Current assets	$0.4M	$0.4M	$3.6M	$2.1M
Current liabilities	$26.1M	$13.8M	$19.2M	$4.8M
Property and equipment, net	$0.1M	$0.1M	$0.1M	$0.1M
Total assets	$1.3M	$0.5M	$3.7M	$2.2M
Total liabilities	$27.6M	$13.9M	$19.7M	$5.1M
Shareholders' equity	−$26.4M	−$13.4M	−$16.0M	−$3.0M
Margins
Gross margin	−31.2%	−12.6%	−43.7%	−37.0%
Operating margin	−669.1%	−671.2%	−1,493.8%	−711.3%
EBITDA margin	−667.0%	−668.5%	−1,484.9%	−706.5%
Net margin	−2,641.0%	−3,308.5%	−1,575.3%	−206.1%
FCF margin	−412.9%	−473.6%	−1,089.1%	−553.1%
Returns
Return on capital employed	31.1%	51.2%	62.0%	361.5%
Return on assets	−2,362.4%	−3,854.0%	−483.4%	−95.3%
Growth
Revenue growth	—	−11.4%	−37.0%	111.4%
Share count change	—	83.0%	286.1%	58.7%
Financial health
Interest coverage	−19.1x	−623.0x	−65.3x	−144.3x
Current ratio	0.0x	0.0x	0.2x	0.4x
Quick ratio	0.0x	0.0x	0.2x	0.4x
Capital allocation
Capex / revenue	5.0%	4.3%	7.9%	1.0%
Stock comp / revenue	161.8%	144.5%	97.7%	149.5%
Quality scores
Piotroski F-score	—	4.0	4.0	5.0
Altman Z''	−317.9	−933.2	−134.5	−197.3
Accruals ratio	−1,997.5%	−3,307.4%	−151.6%	160.0%

Source: SEC EDGAR XBRL filings (CIK 0001849380). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

OneMedNet Corp

What OneMedNet Corp does

Filing details

Earnings calendar · OneMedNet Corp

KIRA’s summary AI analyst

1.Sales and profit

2.Cash and shareholders

3.Financial health

OneMedNet Corp in 30 seconds

Key numbers, fiscal 2025

Revenue

Operating margin

Net income

Free cash flow

Return on capital

Sales and profit

Revenue and margins

Net income and earnings per share

Cash and shareholders

Cash flow

Dividends, buybacks and share count

Insider trades

Financial health

Balance sheet

Returns on capital

Piotroski F-score

All figures

4 years of figures